FTC assails generic-delaying deals

The Federal Trade Commission is none too happy with Big Pharma's dealmaking with generics companies. Drugmakers are using legal settlements with copycat manufacturers to keep cheaper meds off the market, the FTC said, adding that what's good for companies in this instance is bad for consumers.

Over the 12 months ended September 30, almost half of the 33 agreements settling patent lawsuits included a restriction on the generic maker's ability to market a drug in return for compensation, the FTC's report said. The agency has sued to block some of these agreements and is supporting a bill in Congress that would ban them.

These sorts of deals have been on the rise over the past couple of years; there were three in fiscal 2005, 14 in 2006, and 14 last year. And the FTC has had only limited success in unraveling them: two appeals courts in 2005 upheld generic-delaying agreements made by Schering-Plough and AstraZeneca.

- see the FTC statement
- read the story in the Wall Street Journal
- check out Pharmalot's post

Suggested Articles

Pfizer's diagnosis-focused launch strategy for Vyndaqel and Vyndamax is paying off with the meds reaching thousands of patients already.

Pfizer terminated a slew of trial cohorts testing Bavencio in combination with its own experimental drugs, as well as one monotherapy trial.

With its Eli Lilly-partnered Olumiant nearing filing in atopic dermatitis, Incyte's other JAK med Jakafi is also looking for a win in that indication.